



GATC Health

THE QUICKEST PATH TO BETTER DRUGS

Opioid Abatement Settlement Summit

Georgetown University

January 26, 2023

Tyrone Lam, Chief Operating Officer, GATC Health

Novel Treatment for Opioid Addiction

GATC discovered a safer and more effective opioid addiction medication.

Our advanced AI platform accelerates and de-risks drug discovery and testing.

Seeking partners to accelerate and expand research and development.



GATC Health

GATC Health is a science and technology company revolutionizing disease prediction and drug discovery and development through its transformative AI platform and approach, which de-risks drug pipelines and accelerates new therapies to treat disease with accuracy, efficiency and speed never before achieved in medical science. The company's validated and proprietary Multiomics Advanced Technology™ (MAT) platform simulates human biochemistry's billions of interactions for accurate and rapid disease prediction, novel target identification, and drug discovery and development.

GATC's Advanced AI Platform

Models true human physiology.

Analyzes interactions of 400 trillion genetic datapoints in 7 min.

Predicts drug success with 88% accuracy vs current industry lead optimization success rate of ~8%.

Develops quality drug candidates in 3–6 months vs 2–3 years.

GATC completed an extensive retrospective double-blinded analysis using machine learning performance metrics to assess platform results on blinded real-world compounds and successfully predicted drug success with 88% accuracy, and importantly, forecasted drug failure with an unprecedented 84% accuracy rate. With vast improvements in both speed and accuracy, GATC has demonstrated an 11x increase over the current industry lead optimization success rate of approximately 8%.



GATC Health

GATC Addiction Medication Attributes

Doesn't pose a risk for drug abuse.

Maintains sufficient Dopamine levels to increase comfort without euphoria, incentivizing patients to continue treatment.

Promotes remodeling of the brain's limbic system with shifts away from learned addiction patterns by increasing addicted brain neuroplasticity.

Potential for use in treatment of other addictions, such as alcoholism and nicotine.

GATC's novel non-addicting abatement medications will maintain sufficient dopamine levels in the addiction and reward centers to reduce discomfort and agitation while also promoting remodeling of the brain limbic system with shifts away from learned addiction patterns, by increasing addicted brain neuroplasticity. As we conclude our Pre-clinical Testing in the first half of 2023, GATC will confirm our understanding of the specificity, safety, and non-toxicity seen during drug discovery, as well as demonstrate the efficacy of the best candidate abatement compounds.

Addiction Candidates in Preclinical Testing

Evaluation Testing with Opioid (Fentanyl), Cocaine and Addiction.

Fulfilled In-Vitro safety & efficacy criteria with Eurofins.

Preliminary animal testing results with UC Irvine are very promising.

Plan to finish IND enabling preclinical testing with partner(s).



GATC Health

In-vitro testing: All abatement candidate drugs have already fulfilled the safety and efficacy criteria of the EUROFINS primary target safety panels. In-vivo testing is already in process: Animal studies of drug candidates have begun at UC Irvine using 3 groups of Outbred Wistar rats, with each group receiving intraperitoneal injections of a different abatement compound, in controlled studies with Fentanyl-addicted subject rats, to be compared with Control groups of non-addicted subject rats.

Next Steps on Working Together

- Settlement Abatement
- Research Collaboration
- Clinical Trials
- Data Sharing
- Predictive Health Reports
- Commercial Partnerships
- Compliance / Verification



GATC Health

Tyrone Lam, COO

ty@gatchealth.com

760.402.2899 (m)

Opioid Abatement Settlement guidelines include recommendations for allocating a percentage of funds for research and development. GATC Health is open to establishing relationships with states and other municipalities to support their Opioid Abatement goals by accelerating the availability of this significant new abatement tool for their addiction treatment professionals. GATC is also seeking university, non-profit and commercial partnerships within your state for collaborative research, data sharing, clinical trials, and development.